相关临床试验
11
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
5
45.5%
终止
4
36.4%
撤回
2
18.2%
暂无批准数据
- The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies. - Moderna's mRNA-1083 combination vaccine achieved primary endpoints in Phase III trials, demonstrating stronger immune responses than licensed comparator vaccines for both influenza and COVID-19. - AstraZeneca launched FluMist Home in August 2025, marking the first FDA-approved influenza vaccine for self-administration or caregiver delivery at home. - Leading pipeline candidates include Moderna's mRNA-1010 seasonal vaccine, SAB Biotherapeutics' broadly neutralizing antibody SAB-176, and innovative intranasal therapies targeting multiple respiratory viruses.
- DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases. - Recent clinical milestones include Kamada's post-marketing research initiative for CYTOGAM, ACTG's encouraging HIV-CMV study results, and Fortress Biotech's Phase 2 trial initiation for Triplex vaccine. - The CMV pipeline encompasses diverse therapeutic approaches including mRNA vaccines, T-cell therapies, immune globulins, and antiviral compounds from companies like Moderna, Merck Sharp & Dohme, and Chimerix. - Market growth is driven by increasing CMV prevalence and research activities, though high treatment costs and healthcare infrastructure limitations present ongoing challenges.
- Kalaris Therapeutics and AlloVir have finalized their merger, with the combined entity operating under the Kalaris name and trading on Nasdaq as KLRS, led by CEO Andrew Oxtoby. - The merged company has secured approximately $100 million in cash, providing financial runway into Q4 2026 to support the continued development of TH103, a novel anti-VEGF therapy for retinal diseases. - TH103, engineered by Dr. Napoleone Ferrara, aims to address limitations of current neovascular age-related macular degeneration treatments with initial Phase 1 data expected in the second half of 2025.
• A groundbreaking mRNA vaccine (mRNA-1647) demonstrates superior efficacy against cytomegalovirus infection in phase 3 clinical trials, offering new hope for preventing CMV transmission. • The global CMV infections market is projected to experience significant growth across seven major markets, with a diagnosed population of 111,000 cases reported in 2022. • Leading pharmaceutical companies including ModernaTX, Merck Sharp & Dohme, GlaxoSmithKline, and AlloVir are developing innovative therapies to address unmet needs in CMV treatment.
• Allovir Inc. will merge with Kalaris Therapeutics Inc., shifting focus to therapies for neovascular and exudative retinal diseases. • The combined company, Kalaris Therapeutics Inc. (KLRS), will advance TH-103, an anti-VEGF treatment, currently in a Phase I study for neovascular age-related macular degeneration (nAMD). • Phase I study data readout for TH-103 is anticipated in the third quarter of 2025, marking a key milestone for the merged entity's pipeline. • The strategic merger aims to address conditions like nAMD, diabetic macular edema, and retinal vein occlusion, leveraging Kalaris' existing assets.
